| Website | ceptaris.com |
| Category | BioTech |
| Phone | 610-975-9290 |
| Employees | |
| Founded | 2002 |
| TOTAL | $10M |
| FUNDING TOTAL | $10M |
| Series D, 6/12 Vivo Ventures Palo Alto Investors Burrill & Company Aperture Venture Partners Osage Venture Partners BioAdvance | $10M |
| DEBT TOTAL | $15M |
| Debt, 2/12 Silicon Valley Bank Oxford Finance Corporation | $15M |
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris’ investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
